Hormone clue may unmask kidney danger in diabetes

NCT ID NCT06190158

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study investigates whether people with type 2 diabetes who have or are at risk for chronic kidney disease produce too much aldosterone, a hormone that regulates salt and blood pressure. Participants undergo several suppression tests—including oral sodium, saline infusion, and medication challenges—to measure how much aldosterone their bodies produce independently of normal triggers. The goal is to understand if this hidden hormone excess is linked to kidney damage, which could lead to better detection and treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Diagnostic tests including oral sodium, saline, captopril, dexamethasone, and cosyntropin to assess aldosterone production
What this could lead to
If this works, it could identify a treatable hormone imbalance that contributes to kidney disease in people with type 2 diabetes, potentially guiding earlier interventions.
What could go wrong
This is an early-phase diagnostic study, so it won't directly test treatments. The tests may not reliably distinguish the condition, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.